Malignant transformation of ovarian teratoma responded well to immunotherapy after failed chemotherapy: a case report
| Autor: | Xiaohong Li, Xuefeng Tang, Wenlei Zhuo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology endocrine system medicine.medical_specialty endocrine system diseases medicine.medical_treatment Ovary Treatment of lung cancer Malignant transformation 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Ovarian Teratoma Advanced and Specialized Nursing Chemotherapy business.industry Melanoma medicine.disease female genital diseases and pregnancy complications Radiation therapy 030104 developmental biology Anesthesiology and Pain Medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Germ cell tumors business |
| Zdroj: | Annals of Palliative Medicine. 10:8499-8505 |
| ISSN: | 2224-5839 2224-5820 |
| Popis: | Mature cystic teratomas (MCTs), also known as dermoid cysts, are the most common ovarian germ cell tumors and the most common ovarian neoplasms in patients younger than 20 years. MCTs mainly appear as pelvic masses that are made up of different types of well differentiated derivates of at least two germinative cell types. MCT of the ovary is always benign lesions with slow growth and good prognosis. Unfortunately, in about 1-2% of cases, it may undergo malignant transformation. At present, surgical treatment is the preferred option for the early stage of malignant transformation of teratomas, while with a high postoperative recurrence rate. For advanced or recurrent malignant ovarian teratomas, the effect of conventional chemotherapy or radiotherapy is poor, leading to high mortality. Thus, identifying novel treatment for malignant transformed MCTs is an urgently need in clinic. Recently, PD-1 antibody-based immunotherapy has achieved great success in treatment of lung cancer, melanoma, and other malignant tumors. However, its effect on the malignant transformation of ovarian teratomas has not yet been reported. Here we reported a patient who suffered malignant transformation of ovarian teratoma and responded well to camrelizumab, an anti-PD-1 inhibitor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|